[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Qingyuan Zhan\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":156},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,6,0,[8,45,67,88,108,132],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":28,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":34,"lastUpdatePostDateStruct":35,"startDateStruct":38,"completionDateStruct":40,"leadSponsor":42,"locationsCount":4},"100604675","phase-3-adaptive-rct-of-corticosteroids-for-severe-adenovirus-pneumonia-in-adults-100604675",false,"NCT07152600","Adaptive RCT of Corticosteroids for Severe Adenovirus Pneumonia in Adults","An Embedded Adaptive Randomized Controlled Trial of Corticosteroid Therapy for Severe Adenovirus Community-Acquired Pneumonia in Adults","CAPSTONE-AD","Inclusion Criteria:\n\n* Age ≥ 18 years.\n* Admission to the Intensive Care Unit (ICU).\n* Meeting the diagnostic criteria for community-acquired pneumonia (CAP).\n* Meeting at least one of the major diagnostic criteria for severe pneumonia:\n\n  (i) Requirement for endotracheal intubation and mechanical ventilation;\n\n(ii) Septic shock requiring vasopressor therapy after adequate fluid resuscitation.\n\n-Or simultaneously fulfilling three of the minor criteria:\n\n(i) Respiratory rate ≥ 30 breaths\u002Fmin;\n\n(ii) PaO₂\u002FFiO₂ ≤ 250 mmHg;\n\n(iii) Multilobar infiltrates;\n\n(iv) Altered mental status and\u002For disorientation;\n\n(v) Blood urea nitrogen ≥ 20 mg\u002FdL (7.12 mmol\u002FL);\n\n(vi) Leukopenia (white blood cell count \\\u003C 4 × 10⁹\u002FL);\n\n(vii) Thrombocytopenia (platelet count \\\u003C 100 × 10⁹\u002FL);\n\n(viii) Hypothermia (core temperature \\\u003C 36 °C);\n\n(ix) Hypotension (systolic blood pressure \\\u003C 90 mmHg) requiring aggressive fluid resuscitation.\n\n* Confirmed adenovirus etiology: at least one positive nucleic acid test (PCR) or next-generation sequencing (NGS) result for adenovirus in respiratory specimens (respiratory secretions, throat swabs, or bronchoalveolar lavage fluid).\n* Severe community-acquired pneumonia (SCAP) patients admitted to the emergency department\u002Fward\u002FICU due to respiratory failure within \\\u003C 72 hours.\n* Signed informed consent.\n\nExclusion Criteria:\n\n* Patients receiving vasopressor therapy for septic shock at the time of enrollment.\n* Terminally ill patients (expected survival \\\u003C30 days, e.g., advanced malignancy).\n* Clinical history suggesting overt aspiration.\n* Documented active gastrointestinal bleeding.\n* Presence of cystic fibrosis, obstructive pneumonia, active influenza, pulmonary tuberculosis, or fungal infection.\n* Active viral hepatitis or active herpesvirus infection.\n* Bone marrow suppression or HIV infection.\n* Refusal of mechanical ventilation and endotracheal intubation.\n* Uncontrolled hyperglycemia (diabetic ketoacidosis with blood ketones \\>3 mmol\u002FL, or hyperosmolar hyperglycemic state with blood glucose \\>33.3 mmol\u002FL and elevated osmolality).\n* Known allergy to corticosteroids.\n* Patients requiring anti-inflammatory corticosteroids or replacement hydrocortisone for any reason, or those already receiving prednisone \\>15 mg\u002Fday (or equivalent dose of another corticosteroid).\n* Pregnant or breastfeeding women.","ALL","18 Years",{"count":20,"type":21},262,"ESTIMATED","INTERVENTIONAL",[24],"PHASE3","Severe community-acquired pneumonia caused by adenovirus (hereafter referred to as severe adenovirus pneumonia) is one of the common forms of severe community-acquired pneumonia in immunocompetent adults. It predominantly affects young individuals, progresses rapidly, and is associated with a high incidence of respiratory failure and multiple organ dysfunction. At present, there is no effective antiviral therapy available in China, and the reported mortality rate ranges from 41.5% to 80%. How to effectively reduce the mortality of severe adenovirus pneumonia, on the basis of conventional supportive care, is crucial for improving the prognosis of critically ill patients and alleviating the burden on families and society. We are currently conducting an adaptive, randomized, open-label controlled trial aimed at reducing mortality in severe adenovirus pneumonia. The primary objective of this study is to evaluate the efficacy and safety of adjunctive corticosteroid therapy at different dosages, in addition to early standard supportive treatment, in lowering mortality among patients with severe adenovirus pneumonia.",[27],"Adenovirus Infections, Human",[29,30,31,32],"Adenovirus","community-acquired pneumonia","adaptive randomised controled trial","corticosteroids","NOT_YET_RECRUITING","2026-01-20",{"date":36,"type":37},"2026-01-21","ACTUAL",{"date":39,"type":21},"2026-02-01",{"date":41,"type":21},"2027-12-31",{"name":43,"class":44},"Qingyuan Zhan","OTHER",{"id":46,"slug":47,"hasResults":11,"nctId":48,"briefTitle":49,"officialTitle":49,"acronym":4,"eligibilityCriteria":50,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":51,"targetDuration":4,"studyType":22,"phases":53,"briefSummary":56,"conditions":57,"keywords":4,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":60,"lastUpdatePostDateStruct":61,"startDateStruct":63,"completionDateStruct":64,"leadSponsor":66,"locationsCount":4},"100620462","phase-1-early-inflammatory-immune-stratification-and-precision-glucocorticoid-intervention-in-acute-respiratory-failure-induced-by-community-acquired-pneumonia-100620462","NCT07357935","Early Inflammatory-Immune Stratification and Precision Glucocorticoid Intervention in Acute Respiratory Failure Induced by Community-Acquired Pneumonia","Inclusion Criteria:1. Age ≥ 18 years. 2. Admitted to the Intensive Care Unit (ICU) within 48 hours. 3. Meet diagnostic criteria for bacterial community-acquired pneumonia (CAP). 4. Meet at least one severity criterion: a) Receiving mechanical ventilation for acute respiratory failure with PEEP ≥ 5 cmH2O; OR b) On high-flow oxygen with FiO2 ≥ 0.5 and PaO2\u002FFiO2 ratio ≤ 250 mmHg; OR c) On a reservoir oxygen mask with PaO2 below the specified flow threshold (see protocol). 5. Signed informed consent.\n\n\\-\n\nExclusion Criteria: 1. Suspected aspiration pneumonia. 2. Invasive mechanical ventilation within 14 days prior to admission. 3. Diagnosis of hospital-acquired or ventilator-associated pneumonia (HAP\u002FVAP). 4. Positive for influenza virus, active tuberculosis, or fungal infection (except Pneumocystis jirovecii). 5. Active viral hepatitis or herpesvirus infection. 6. Hypersensitivity to glucocorticoids, or contraindications as judged by the investigator (e.g., severe concurrent infections, active gastrointestinal hemorrhage). 7. High-dose glucocorticoid therapy (\\>1 mg\u002Fkg\u002Fday prednisone equivalent) within 30 days for underlying disease. 8. Death within 24 hours of ICU admission. 9. Pregnancy or lactation. 10. Participation in other interventional studies or refusal to participate.\n\n\\-",{"count":52,"type":21},500,[54,55],"PHASE1","PHASE2","This is a prospective, multicenter, interventional cohort study aimed at constructing a high-quality, dynamic multimodal database for patients with acute respiratory failure caused by community-acquired pneumonia (CAP-ARF). The study focuses on bacterial CAP-ARF patients receiving standardized glucocorticoid therapy to investigate the heterogeneity of treatment responses under different etiologies and immune statuses. The goal is to provide a data foundation for precise immune stratification and identification of glucocorticoid-sensitive populations.",[58,59],"Acute Respiratory Failure","Community-Acquired Pneumonia","2026-01-14",{"date":62,"type":37},"2026-01-22",{"date":39,"type":21},{"date":65,"type":21},"2028-10-01",{"name":43,"class":44},{"id":68,"slug":69,"hasResults":11,"nctId":70,"briefTitle":71,"officialTitle":72,"acronym":4,"eligibilityCriteria":73,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":74,"targetDuration":4,"studyType":22,"phases":76,"briefSummary":77,"conditions":78,"keywords":80,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":81,"lastUpdatePostDateStruct":82,"startDateStruct":83,"completionDateStruct":85,"leadSponsor":87,"locationsCount":4},"100620072","phase-3-adaptive-rct-of-corticosteroids-for-severe-chlamydia-psittaci-pneumonia-in-adults-100620072","NCT07352865","Adaptive RCT of Corticosteroids for Severe Chlamydia Psittaci Pneumonia in Adults","An Embedded Adaptive Randomized Controlled Trial of Corticosteroid Therapy for Severe Chlamydia Psittaci Community-Acquired Pneumonia in Adults","Inclusion Criteria:\n\n* Age ≥ 18 years.\n* Admission to the Intensive Care Unit (ICU).\n* Meeting the diagnostic criteria for community-acquired pneumonia (CAP).\n* Meeting at least one of the major diagnostic criteria for severe pneumonia:\n\n  (i) Requirement for endotracheal intubation and mechanical ventilation;\n\n(ii) Septic shock requiring vasopressor therapy after adequate fluid resuscitation.\n\n-Or simultaneously fulfilling three of the minor criteria:\n\n(i) Respiratory rate ≥ 30 breaths\u002Fmin;\n\n(ii) PaO₂\u002FFiO₂ ≤ 250 mmHg;\n\n(iii) Multilobar infiltrates;\n\n(iv) Altered mental status and\u002For disorientation;\n\n(v) Blood urea nitrogen ≥ 20 mg\u002FdL (7.12 mmol\u002FL);\n\n(vi) Leukopenia (white blood cell count \\\u003C 4 × 10⁹\u002FL);\n\n(vii) Thrombocytopenia (platelet count \\\u003C 100 × 10⁹\u002FL);\n\n(viii) Hypothermia (core temperature \\\u003C 36 °C);\n\n(ix) Hypotension (systolic blood pressure \\\u003C 90 mmHg) requiring aggressive fluid resuscitation.\n\n* Confirmed Chlamydia psittaci etiology (psittacosis): at least one positive nucleic acid test (PCR\u002FRT-PCR) or next-generation sequencing (NGS) result for Chlamydia psittaci in respiratory specimens (respiratory secretions, throat swabs, or bronchoalveolar lavage fluid).\n* Severe community-acquired pneumonia (SCAP) patients admitted to the emergency department\u002Fward\u002FICU due to respiratory failure within \\\u003C 72 hours.\n* Signed informed consent.\n\nExclusion Criteria:\n\n* Patients receiving vasopressor therapy for septic shock at the time of enrollment.\n* Terminally ill patients (expected survival \\\u003C30 days, e.g., advanced malignancy).\n* Clinical history suggesting overt aspiration.\n* Documented active gastrointestinal bleeding.\n* Presence of cystic fibrosis, obstructive pneumonia, active influenza, pulmonary tuberculosis, or fungal infection.\n* Active viral hepatitis or active herpesvirus infection.\n* Bone marrow suppression or HIV infection.\n* Refusal of mechanical ventilation and endotracheal intubation.\n* Uncontrolled hyperglycemia (diabetic ketoacidosis with blood ketones \\>3 mmol\u002FL, or hyperosmolar hyperglycemic state with blood glucose \\>33.3 mmol\u002FL and elevated osmolality).\n* Known allergy to corticosteroids.\n* Patients requiring anti-inflammatory corticosteroids or replacement hydrocortisone for any reason, or those already receiving prednisone \\>15 mg\u002Fday (or equivalent dose of another corticosteroid).\n* Pregnant or breastfeeding women.",{"count":75,"type":21},100,[24],"Severe community-acquired pneumonia caused by psittacosis is a form of atypical-pathogen community-acquired pneumonia that often requires critical care management. It can occur in immunocompetent adults, has an abrupt onset and rapid progression, and may quickly deteriorate to profound hypoxemia, acute respiratory distress syndrome, and multiple organ dysfunction, frequently necessitating ICU admission. In a multicenter cohort from 19 tertiary hospitals in China with metagenomic next-generation sequencing (mNGS)-confirmed severe CAP complicated by acute hypoxemic respiratory failure, approximately 44% of patients required invasive mechanical ventilation and ICU mortality was 8.9%, indicating a substantial risk of death and severe morbidity among critically ill patients. The World Health Organization (WHO) reported an increase in cases across several European countries from 2023 to early 2024, with five deaths, suggesting that the disease burden and public health significance of psittacosis may have been underestimated for a prolonged period.\n\nAt present, the cornerstone of psittacosis pneumonia management is early recognition and timely pathogen-directed antibiotic therapy (tetracyclines, particularly doxycycline, as first-line treatment), together with well-established organ-support strategies. Optimizing comprehensive management beyond early standard supportive care and guideline-concordant antimicrobial therapy (including targeted antibiotics and organ support) to further reduce mortality in severe psittacosis pneumonia is therefore of major clinical importance for improving outcomes in critically ill patients and alleviating the burden on families and society. Accordingly, we plan to conduct an adaptive, randomized, open-label, controlled trial to evaluate the efficacy and safety of adjunctive corticosteroid regimens at different doses, in addition to early standard supportive care, for reducing mortality in patients with severe psittacosis pneumonia.",[79],"Psittacosis",[79,30,31,32],"2026-01-13",{"date":34,"type":37},{"date":84,"type":21},"2026-01-15",{"date":86,"type":21},"2028-11-30",{"name":43,"class":44},{"id":89,"slug":90,"hasResults":11,"nctId":91,"briefTitle":92,"officialTitle":93,"acronym":94,"eligibilityCriteria":95,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":96,"targetDuration":4,"studyType":22,"phases":98,"briefSummary":99,"conditions":100,"keywords":102,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":103,"lastUpdatePostDateStruct":104,"startDateStruct":105,"completionDateStruct":106,"leadSponsor":107,"locationsCount":4},"100619967","phase-3-adaptive-rct-of-corticosteroids-for-severe-influenza-pneumonia-in-adults-100619967","NCT07351500","Adaptive RCT of Corticosteroids for Severe Influenza Pneumonia in Adults","An Embedded Adaptive Randomized Controlled Trial of Corticosteroid Therapy for Severe Influenza Community-Acquired Pneumonia in Adults","CAPSTONE-IFV","Inclusion Criteria:\n\n* Age ≥ 18 years.\n* Admission to the Intensive Care Unit (ICU).\n* Meeting the diagnostic criteria for community-acquired pneumonia (CAP).\n* Meeting at least one of the major diagnostic criteria for severe pneumonia:\n\n  (i) Requirement for endotracheal intubation and mechanical ventilation;\n\n(ii) Septic shock requiring vasopressor therapy after adequate fluid resuscitation.\n\n-Or simultaneously fulfilling three of the minor criteria:\n\n(i) Respiratory rate ≥ 30 breaths\u002Fmin;\n\n(ii) PaO₂\u002FFiO₂ ≤ 250 mmHg;\n\n(iii) Multilobar infiltrates;\n\n(iv) Altered mental status and\u002For disorientation;\n\n(v) Blood urea nitrogen ≥ 20 mg\u002FdL (7.12 mmol\u002FL);\n\n(vi) Leukopenia (white blood cell count \\\u003C 4 × 10⁹\u002FL);\n\n(vii) Thrombocytopenia (platelet count \\\u003C 100 × 10⁹\u002FL);\n\n(viii) Hypothermia (core temperature \\\u003C 36 °C);\n\n(ix) Hypotension (systolic blood pressure \\\u003C 90 mmHg) requiring aggressive fluid resuscitation.\n\n* Confirmed influenza virus etiology: at least one positive nucleic acid test (RT-PCR\u002FPCR) or next-generation sequencing (NGS) result for influenza virus in respiratory specimens (respiratory secretions, throat swabs, or bronchoalveolar lavage fluid).\n* Severe community-acquired pneumonia (SCAP) patients admitted to the emergency department\u002Fward\u002FICU due to respiratory failure within \\\u003C 72 hours.\n* Signed informed consent.\n\nExclusion Criteria:\n\n* Patients receiving vasopressor therapy for septic shock at the time of enrollment.\n* Terminally ill patients (expected survival \\\u003C30 days, e.g., advanced malignancy).\n* Clinical history suggesting overt aspiration.\n* Documented active gastrointestinal bleeding.\n* Presence of cystic fibrosis, obstructive pneumonia, active influenza, pulmonary tuberculosis, or fungal infection.\n* Active viral hepatitis or active herpesvirus infection.\n* Bone marrow suppression or HIV infection.\n* Refusal of mechanical ventilation and endotracheal intubation.\n* Uncontrolled hyperglycemia (diabetic ketoacidosis with blood ketones \\>3 mmol\u002FL, or hyperosmolar hyperglycemic state with blood glucose \\>33.3 mmol\u002FL and elevated osmolality).\n* Known allergy to corticosteroids.\n* Patients requiring anti-inflammatory corticosteroids or replacement hydrocortisone for any reason, or those already receiving prednisone \\>15 mg\u002Fday (or equivalent dose of another corticosteroid).\n* Pregnant or breastfeeding women.",{"count":97,"type":21},496,[24],"Severe community-acquired pneumonia caused by influenza virus (hereafter referred to as severe influenza pneumonia) is a major etiology of community-acquired pneumonia leading to acute respiratory failure and ICU admission. It can rapidly progress to profound hypoxemia, acute respiratory distress syndrome (ARDS), and multiple organ dysfunction, and remains associated with substantial mortality. Although antiviral therapy-typically neuraminidase inhibitors-and well-established organ-support strategies are currently available, outcomes in a subset of critically ill patients remain poor despite antiviral and supportive care alone, with ICU mortality reported to be as high as 20-30%. Therefore, identifying effective adjunctive interventions beyond standard care to further reduce mortality in severe influenza pneumonia is of great clinical importance for improving outcomes in critically ill patients and alleviating the burden on families and society.\n\nHowever, the use of systemic corticosteroids in influenza-associated community-acquired pneumonia (CAP) has long been highly controversial. Multiple studies have suggested that corticosteroid therapy may increase mortality among patients with H1N1 influenza. During the early phase of the COVID-19 pandemic, treatment strategies drew on this evidence and generally advised caution regarding corticosteroid use; subsequently, randomized controlled trials (RCTs) such as RECOVERY and REMAP-CAP demonstrated that low-dose corticosteroids (e.g., dexamethasone 6 mg\u002Fday) reduce mortality in patients with pneumonia requiring oxygen therapy. Recently, the U.S. Centers for Disease Control and Prevention (CDC) has emphasized the urgent need for RCTs evaluating low- to moderate-dose corticosteroids or other immunomodulatory agents to clarify their role in the management of influenza-associated CAP. Collectively, these observations underscore the urgency of pathogen-directed anti-inflammatory strategies for CAP-associated acute respiratory failure.\n\nAccordingly, we plan to conduct an adaptive, randomized, open-label, controlled trial to evaluate the efficacy and safety of adjunctive corticosteroid regimens at different doses, in addition to early standard supportive care (including guideline-concordant antiviral therapy and organ support), for reducing mortality in patients with severe influenza pneumonia.",[101],"Influenza",[101,30,31,32],"2026-01-12",{"date":34,"type":37},{"date":84,"type":21},{"date":86,"type":21},{"name":43,"class":44},{"id":109,"slug":110,"hasResults":11,"nctId":111,"briefTitle":112,"officialTitle":113,"acronym":114,"eligibilityCriteria":115,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":116,"targetDuration":4,"studyType":22,"phases":118,"briefSummary":119,"conditions":120,"keywords":122,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":125,"lastUpdatePostDateStruct":126,"startDateStruct":128,"completionDateStruct":130,"leadSponsor":131,"locationsCount":4},"100604676","phase-3-corticosteroids-for-pjp-in-non-hiv-immunocompromised-adults-100604676","NCT07152613","Corticosteroids for PJP in Non-HIV Immunocompromised Adults","An Embedded Adaptive Randomized Controlled Trial of Corticosteroid Therapy for Pneumocystis Jirovecii Pneumonia (PJP) in Non-HIV Immunocompromised Patients","CAPSTONE-PJP","Inclusion Criteria:\n\nAge ≥ 18 years.\n\nAdmission to the Intensive Care Unit (ICU).\n\nMeeting the diagnostic criteria for community-acquired pneumonia (CAP).\n\nMeeting at least one of the major diagnostic criteria for severe pneumonia:\n\n(i) Requirement for endotracheal intubation and mechanical ventilation;\n\n(ii) Septic shock requiring vasopressor therapy after adequate fluid resuscitation.\n\nOr simultaneously fulfilling three of the minor criteria:\n\n(i) Respiratory rate ≥ 30 breaths\u002Fmin;\n\n(ii) PaO₂\u002FFiO₂ ≤ 250 mmHg;\n\n(iii) Multilobar infiltrates;\n\n(iv) Altered mental status and\u002For disorientation;\n\n(v) Blood urea nitrogen ≥ 20 mg\u002FdL (7.12 mmol\u002FL);\n\n(vi) Leukopenia (white blood cell count \\\u003C 4 × 10⁹\u002FL);\n\n(vii) Thrombocytopenia (platelet count \\\u003C 100 × 10⁹\u002FL);\n\n(viii) Hypothermia (core temperature \\\u003C 36 °C);\n\n(ix) Hypotension (systolic blood pressure \\\u003C 90 mmHg) requiring aggressive fluid resuscitation.\n\nConfirmed PJ etiology: at least one positive nucleic acid test (PCR) or next-generation sequencing (NGS) result for Pneumocystis jirovecii in respiratory specimens (respiratory secretions, throat swabs, or bronchoalveolar lavage fluid).\n\nSevere community-acquired pneumonia (SCAP) patients admitted to the emergency department\u002Fward\u002FICU due to respiratory failure within \\\u003C 72 hours.\n\nSigned informed consent.\n\nExclusion Criteria:\n\n* Age \\\u003C 18 years.\n* Pregnant or breastfeeding women.\n* HIV infection.\n* No targeted PJP therapy administered or therapy not according to standard protocol.\n* Diagnosis of PJP \\>7 days prior to MICU admission.\n* Use of corticosteroids for PJP prior to MICU admission.\n* Requirement for high-dose baseline corticosteroid therapy for other conditions (prednisone ≥ 0.5 mg\u002Fkg\u002Fday or equivalent).\n* Any contraindication to corticosteroid use as judged by the investigator (e.g., severe concurrent infectious disease, severe gastrointestinal bleeding).\n* Discharge or death within 48 hours after intervention.\n* Participation in other clinical studies or refusal to participate in this study.",{"count":117,"type":21},240,[24],"Pneumocystis jirovecii pneumonia (PJP) is one of the common severe complications in immunocompromised patients, with a reported mortality rate of 60-80%. Reducing mortality from PJP is crucial for improving outcomes in critically ill non-HIV immunocompromised patients and alleviating the burden on families and society. To address this medical challenge, our institution is conducting a study aimed at lowering PJP-related mortality. Specifically, we are performing an adaptive, randomized, open-label controlled trial in patients with severe PJP. The primary objective of this study is to scientifically evaluate the efficacy and safety of adjunctive corticosteroids at different dosages, in addition to early standard supportive care, for reducing mortality in severe PJP",[121],"Pneumocystis Jiroveci Pneumonia",[30,123,124,32],"Pneumocystis jiroveci","non-HIV","2025-09-02",{"date":127,"type":37},"2025-09-09",{"date":129,"type":21},"2025-09-08",{"date":41,"type":21},{"name":43,"class":44},{"id":133,"slug":134,"hasResults":11,"nctId":135,"briefTitle":136,"officialTitle":137,"acronym":138,"eligibilityCriteria":139,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":140,"targetDuration":4,"studyType":22,"phases":142,"briefSummary":143,"conditions":144,"keywords":146,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":149,"lastUpdatePostDateStruct":150,"startDateStruct":152,"completionDateStruct":153,"leadSponsor":155,"locationsCount":4},"100604674","phase-2-randomized-adaptive-platform-trial-of-pathogen-directed-anti-inflammatory-therapy-in-severe-community-acquired-pneumoniacore-protocal-100604674","NCT07152587","Randomized Adaptive Platform Trial of Pathogen-Directed Anti-inflammatory Therapy in Severe Community-Acquired Pneumonia(Core Protocal)","Randomized, Embedded, Multifactorial, Adaptive Platform Trial of Pathogen-Directed Precision Anti-inflammatory Therapy in Severe Community-Acquired Pneumonia(Core Protocal)","PANDA-SCAP","Inclusion Criteria:\n\n* Admission to ICU;\n\n  * Age ≥ 18 years;\n\n    * ICU length of stay ≤ 48 hours; ④ Meeting the IDSA\u002FATS diagnostic criteria for SCAP.\n\nExclusion Criteria:\n\n* Confirmed diagnosis of hospital-acquired pneumonia (HAP) or ventilator-associated pneumonia (VAP);\n\n  * Expected death within 24 hours;\n\n    * Presence of septic shock prior to randomization; ④ History of allergy or contraindications to corticosteroids (e.g., active gastrointestinal bleeding, severe osteoporosis, uncontrolled hyperglycemia, bone marrow suppression);\n\n      * Active fungal (except Pneumocystis jirovecii), tuberculosis, or hepatitis infection;\n\n        * Receiving ongoing corticosteroid therapy at a dose equivalent to prednisone \\> 1 mg\u002Fkg\u002Fday due to underlying disease; ⑦ Participation in this trial within the past 90 days; ⑧ Refusal to sign informed consent.",{"count":141,"type":21},1500,[55,24],"Severe community-acquired pneumonia (sCAP) has a high mortality rate of 25-50%. Excessive host inflammatory responses contribute to poor outcomes. Corticosteroid therapy may provide benefit; however, the optimal dosage remains unclear, and it is uncertain whether all etiologies (e.g., Pneumocystis jirovecii, adenovirus, influenza) of sCAP can benefit equally.\n\nThis study will first establish a comprehensive trial platform based on a prospective sCAP cohort, embedding a randomized, multifactorial, adaptive platform trial (APT). The response-adaptive design will increase the likelihood of patients being assigned to more effective treatment arms, while Bayesian statistical modeling will dynamically assess the efficacy of interventions, allowing early achievement of study endpoints.\n\nAt the starting stage, two pathogen-specific APTs will be conducted, focusing on adenovirus- and pneumocystis Jirovecii-induced sCAP. Patients admitted to the ICU with confirmed diagnoses of adenovirus or pneumocystis Jirovecii-associated sCAP will be randomized into a control group or one of two corticosteroid dosage groups. The primary endpoint will be 28-day all-cause mortality. Completion of these APTs will provide a theoretical basis for novel anti-inflammatory strategies in sCAP.\n\nMoreover, this platform will serve as an essential research infrastructure for the efficient evaluation of new therapeutic options in the event of emerging or re-emerging respiratory pathogens causing sCAP in the future.",[145],"Severe Community-acquired Pneumonia (sCAP)",[30,147,148,32],"adaptive platform trial","pathogen directed","2025-08-26",{"date":151,"type":37},"2025-09-03",{"date":129,"type":21},{"date":154,"type":21},"2035-12-31",{"name":43,"class":44},""]